#1Omnicell Investor Relations November 2, 2023 :i#2Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2023 guidance, strategic and growth opportunities, other expectations and other non-historical information. Without limiting the foregoing, statements including the words "expect," "intend," "may," "will," "should," "would," "could," "plan," "potential," "anticipate," "believe," "forecast," "guidance," "outlook," "goals," "target," "estimate," "seek," "predict," "project," and similar expressions are intended to identify forward-looking statements. Forward- looking statements are subject to the occurrence of many events outside Omnicell's control and are subject to various risks and uncertainties, including those described below. Among other things, there can be no assurance that Omnicell's actual results will not differ, perhaps substantially, from the targets and expectations contained in this presentation. Such statements also include, but are not limited to, Omnicell's projected bookings, revenues, including product, service, technical services and Advanced Services revenues, respectively, non-GAAP EBITDA, non-GAAP earnings per share, and estimated total addressable market; planned and existing products and services and the related expected benefits; and statements about Omnicell's strategy, objectives, mission and vision, including its corporate responsibility (innovation, environment, social and governance) goals and strategies, transitioning to selling more products and services on a subscription basis, and growth opportunities. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) unfavorable general economic and market conditions, including the impact and duration of inflationary pressures, (ii) ability to realize the benefits of our expense containment efforts, (iii) Omnicell's ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (iv) reduction in demand in the capital equipment market or reduction in the demand for or adoption of our solutions, systems, or services, (v) delays in installations of our medication management solutions or our more complex medication ackaging systems, (vi) risks related to Omnicell's investments in new business strategies or initiatives, includin its transition to selling more products and services on a subscription basis, and its ability to acquire companies, businesses, or technologies and successfully integrate such acquisitions, (vii) risks related to failing to maintain expected service levels when providing our Advanced Services or retaining our Advanced Services customers, (viii) Omnicell's ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, (ix) risks related to climate change, legal, regulatory or market measures to address climate change and related emphasis on ESG matters by various stakeholders, (x) changes to the 340B Program, (xi) Omnicell's substantial debt, which could impair its financial flexibility and access to capital, (xii) covenants in our credit agreement could restrict our business and operations, (xiii) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (xiv) risks presented by government regulations, legislative changes, fraud and anti-kickback statues, products liability claims, the outcome of legal proceedings, and other legal obligations related to healthcare, privacy, data protection, and information security, including any potential governmental investigations and enforcement actions, litigation, fines and penalties, exposure to indemnification obligations or other liabilities, and adverse publicity as a result of the previously disclosed ransomware incident, (xv) any disruption in Omnicell's information technology systems and breaches of data security or cyber-attacks on its systems or solutions, including the previously disclosed ransomware incident and any potential adverse legal, reputational, and financial effects that may result from it and/or additional cybersecurity incidents, as well as the effectiveness of business continuity plans during any future cybersecurity incidents, (xvi) risks associated with operating in foreign countries, (xvii) Omnicell's ability to recruit and retain skilled and motivated personnel, (xviii) Omnicell's ability to protect its intellectual property, (xix) risks related to the availability and sources of raw materials and components or price fluctuations, shortages, or interruptions of supply, (xx) Omnicell's dependence on a limited number of suppliers for certain components, equipment, and raw materials, as well as technologies provided by third-party vendors, (xxi) fluctuations in quarterly and annual operating results, may make our future operating results difficult to predict; (xxii) failing to meet (or significantly exceeding) our publicly announced financial guidance; and (xxiii) other risks and uncertainties further described in the "Risk Factors" section of Omnicell's most recent Annual Report on Form 10-K, as well as in Omnicell's other reports filed with or furnished to the United States Securities and Exchange Commission ("SEC"), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law Non-GAAP Financial Information This presentation contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP"), including Q3-2023 non-GAAP gross margin, non-GAAP operating expense, non-GAAP EBITDA, and non-GAAP earnings per share, 2017 and Q3-2023 liquidity and 2017 and Q3-2023 net debt/EBITDA, guidance with respect to 2023 non-GAAP EBITDA and non-GAAP earnings per share. Reconciliations of the 2017 and Q3-2023 non-GAAP financial measures to the most directly comparable GAAP measures are included in the Appendix to this presentation. Our 2023 guidance for non-GAAP EBITDA and non-GAAP earnings per share, exclude certain items, which include, but are not limited to, unusual gains and losses, costs associated with future restructurings, acquisition-related expenses, and certain tax and litigation outcomes. These excluded items may be significant. We do not provide a reconciliation of forward-looking non-GAAP guidance or targets to the comparable GAAP measures as these items are inherently uncertain and difficult to estimate and cannot be predicted without unreasonable effort. We believe such a reconciliation would imply a degree of precision that could be confusing or misleading to investors. These items may also have a material impact on GAAP earnings per share and GAAP net income in future periods. As such, these forward-looking non-GAAP financial measures are limited in their utility. for evaluating our future operating results in accordance with GAAP. OMNICELL, the Omnicell logo, and ENLIVENHEALTH are registered trademarks of Omnicell, Inc. or one its subsidiaries. © 2023 Omnicell, Inc. 2#3Our Mission Be the clinician's most trusted partner for medication management. We are dedicated to continuously deliver innovative technology that helps our customers improve patient care, for everyone. Our Vision Deliver the most compelling automation and services that accelerate pharmacy perfection. © 2023 Omnicell, Inc. 1521 BAR 3#4Our Strategy Fundamentally transform the pharmacy care delivery model by delivering a set of services that touch the entire continuum of care, built on a single cloud platform. © 2023 Omnicell, Inc. → ASSESS Point of Care PRESCRIBE Central Pharmacy INPATIENT Specialty Retail Home Pharmacy OUTPATIENT ONE PLATFORM ADMINISTER →DISPENSE 4#5Omnicell: Compelling Growth Opportunities 1 Category creator transforming the pharmacy care delivery model 2 Leading strategic partner to health systems in large and growing market segments with $90 Billion+ Total Addressable Market (TAM)1 3 Resilient, long-term revenue growth accelerated by strong bookings, backlog and upgrade cycles Demonstrated track record of growth built on a platform of intelligent infrastructure, spanning medication management across the continuum of care Leveraging our market-leading installed base to drive recurring revenue growth in Advanced Services 4 © 2023 Omnicell, Inc. 1. Represents estimated cumulative TAM over 10 years as of 5/31/2022 and includes the United States, UK&I, Germany, France, Spain, Kingdom of Saudi Arabia and Australia/New Zealand.#61 The Autonomous Pharmacy Framework an Industry Vision Non-Autonomous Pharmacy . Minimal to no automation • Data primarily managed on paper or in disparate spreadsheets Pharmacists heavily engaged in distribution with little direct patient interaction. Technicians and nurses spend time on manual drug management (purchasing, locating, counting) Level 1 Ⓒ 6 O Bo 8 Performance Elements © 2023 Omnicell, Inc. Limited Autonomous Pharmacy • Some automation, including some barcode tracking • Data managed disparately across sites with some visibility • Pharmacists largely focused on distribution and verification. Technicians and nurses manually responsible for most drug management with light automated support Level 2 Ⓒ 0 8 Safety Financials Efficiency O B 8 Bo 8 Compliance People Intermediate Autonomous Pharmacy . Majority of processes automated, with barcode tracking applied widely Data integrated across enterprise and mostly visible • Pharmacists somewhat focused on medication distribution, with some direct patient care. Technicians focus on manual procurement and controlled substances, and nurses rely on automated dispensing Level 3 Ⓒ b@ O B Level 4 DO Highly Autonomous Pharmacy . Extensive automation with few gaps across processes • Near complete data visibility, offering workflow optimization. and real-time insights Ⓒ . Pharmacists routinely involved in direct patient care, population health initiatives, and clinical programs. Technicians maintain automation and use workflow app, and nurses focus most of their time on patient care & 20 B (4 Level 5 Fully Autonomous Pharmacy . Complete process automation, tracking each dose as a node on the network . Complete data visibility, real-time workflow optimization, and predictive intelligence Pharmacists realize full scope of their role in direct patient care and clinical program optimization. Technicians ensure optimal function of automation and use workflow app, and nurses focus on direct patient care Outcomes 100% ✔ Data Visibility Time Spent on Clinical Activity 0 ✓ Medication Errors ✓ Medication Waste ✓ Human Touches Pre-administration ✔ Regulatory To Patient Compliance |||| 10 B₂ & The Autonomous Pharmacy Framework: A Transformative Vision for the Medication Management Process 6#71 Our Comprehensive Solutions Fundamentally Deliver Better Healthcare Value IV Compounding Service Point of Care Central Pharmacy Dispensing Service © 2023 Omnicell, Inc. Somal Inpatient ela IV Compounding Point of Care Central Distribution Inventory Management Omnicell Connected Intelligent Infrastructure Retail in one Home Inventory Optimization Service $ Specialty 000 Pharmacy Services Outpatient EnlivenHealthⓇ 7#82 Leader in Large and Growing Segments Omnicell is growing its leadership position across a potential $90 Billion+ TAM Estimated TAM Opportunity¹ $22 Billion Retail $19 Billion Specialty Pharmacy Services $90 Billion+ TOTAL TAM $19 Billion Point of Care $32 Billion Central Pharmacy © 2023 Omnicell, Inc. 1. Represents estimated cumulative TAM over 10 years as of 5/31/2022 and includes the United States, UK&I, Germany, France, Spain, Kingdom of Saudi Arabia and Australia/New Zealand. 8#93 Revenue Growth Drivers Deep Customer Relationships & Robust Backlog Multiple Growth Drivers © 2023 Omnicell, Inc. Strong position within the top 300 U.S. health systems Robust backlog of $1.215 Billion as of 12/31/2022 Customers increasingly turning to Omnicell for our platform-based approach to medication management Expansion opportunities within existing customer base Advanced Services expand our TAM Continued opportunities for competitive conversions 9#103 Advanced Services Accelerating Recurring Revenue Growth Advanced Services (% of Total Revenue) 6% 2020 10% 2021 Targeting 18% of total revenue for 2023 14% 2022 18% 2023E NOTE: Includes Central Pharmacy Dispensing Service (service portion), IV Compounding Service (service portion), EnlivenHealth solutions, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, and other software solutions. © 2023 Omnicell, Inc. Leveraging established channels and strong customer relationships Strong demand driven by increasing provider digitization and need to evolve medication supply chain Omnicell's cloud-based services designed to enable better outcomes Subscription-based, recurring revenue streams Advanced Services expand our TAM 10#113 Advanced Services Business Model Tech-Enabled Services Model (IVCS and CPDS) Recurring Advanced Services Revenue YEAR 1 Product Revenue Cash Received Net Sales Type Lease Run Down YEAR 1 SaaS and Software Subscriptions Model Recurring Advanced Cash Services Revenue Received © 2023 Omnicell, Inc. YEAR 2 Recurring Advanced Services Revenue Cash Received Net Sales Type Lease Run Down YEAR 2 Recurring Advanced Cash Services Revenue Received. Customer Example YEAR 3 Recurring Advanced Services Revenue Cash Received Net Sales Type Lease Run Down YEAR 3 Recurring Advanced Cash Services Revenue Received YEAR 4 - 7 Recurring Advanced Services Revenue Cash Received Net Sales Type Lease Run Down YEAR 4 - 5 Recurring Advanced Cash Services Revenue Received End of year 7 Net sales type lease balance: $0 Transition to Advanced Services business model anticipated to provide: 1) Increased value to customers 2) Higher revenue versus previous model and 3) Highly visible, recurring revenue & cash flow 11#124 Strong Balance Sheet Free cash flow projected to grow slower than EBITDA as Omnicell reinvests in the transformation to Advanced Services Liquidity and capital structure support growth strategy © 2023 Omnicell, Inc. $32M $447M Cash and Cash Equivalents $210M $569M Total Debt $1,016M Total Assets $313M $2,222M As of December 31, 2017 $947M Liquidity¹ $554M As of September 30, 2023 2. Net Debt / EBITDA = (Total Debt - Cash and Cash Equivalents) / Trailing Twelve Month Non-GAAP EBITDA DISCLAIMER: See Appendix for a reconciliation of 2017 and Q3-2023 Net Debt / EBITDA and 2017 and Q3-2023 Liquidity to their most directly comparable GAAP financial measures. $1,187M Total Equity 1.9x 0.9x Net Debt / EBITDA² 1. Liquidity Revolver Availability ($500M) + Cash and Cash Equivalents ($447M); As of October 10, 2023, the Company entered into a Second Amended and Restated Credit Agreement under which $350M of funds are available. The amount of Revolver Availability is dependent on financial covenants. 12#13Backlog¹ ($Million) By type: Product Backlog Advanced Services Backlog² Total Backlog By duration and type: Short-Term Product Backlog Long-Term Product Backlog Short-Term Advanced Services Backlog² Long-Term Advanced Services Backlog² Total Backlog © 2023 Omnicell, Inc. As of December 31, 2022 $797 $418 $1,215 As of December 31, 2022 $503 $294 $49 $369 $1,215 As of December 31, 2021 $977 $277 $1,254 As of December 31, 2021 $745 $232 $37 $240 $1,254 1. Backlog is the dollar amount of bookings that have not yet been recognized as revenue. We consider backlog that is expected to be converted to revenues in more than twelve months to be long-term backlog. We believe a majority of long-term product backlog will be convertible into revenues in 12-24 months. Long-term Advanced Services backlog typically represents multi-year subscription agreements (usually with contractual terms of 2-7 years, some of which have not yet been implemented) that will be converted to revenue ratably over the contractual term. 2. Includes only the value of Advanced Services non-cancelable contracts with minimum commitments. 13#14Total Year Revenue Composition GAAP ($Million) Connected Devices, Software Licenses, & Other Consumables Technical Services Advanced Services Total Revenue Advanced Services % of Total Revenue Recurring % of Total Revenue Recurring vs Non Recurring Non Recurring Product Recurring Recurring Category Recurring Product Service Service Actual TY-2021 $739 $73 $207 $113 $1,132 10% 35% Year over Year (YoY) Change % 32% -3% 2% 109% 27% Actual TY-2022 $828 $75 $207 $186 $1,296 14% 36% YOY Change % 12% 3% 0% 65% 14% Updated Guidance TY-2023 $705-$715 $222-$227 $208-$213 $1,135-$1,155 18% YOY Change % (Mid-Point) -21% 9% 13% -12% 1. Connected Devices, Software Licenses, and other include, but are not limited to, XT Series automated dispensing systems and products related to Central Pharmacy Dispensing Service and IV Compounding Service. © 2023 Omnicell, Inc. 2. Includes Central Pharmacy Dispensing Service (service portion), IV Compounding Service (service portion), Enliven Health solutions, Specialty Pharmacy Services, 340B solutions, Inventory Optimization Service, and other software solutions.. 14#15Financial Snapshot Total Revenues Non-GAAP Gross Margin % Q3-2023 Non-GAAP Operating Expenses Non-GAAP EBITDA Non-GAAP Diluted Earnings Per Share © 2023 Omnicell, Inc. Results $299 Million 45.7% $109 Million $41 Million $0.62 YOY Change % -14% -180bps -6% -33% -38% See Appendix for a reconciliation of Q3-2023 Non-GAAP Gross Margin, Q3-2023 Non-GAAP Operating Expenses, Q3-2023 Non-GAAP EBITDA and Q3-2023 Non-GAAP Diluted Earnings Per Share to their most directly comparable GAAP financial measures. 15#16Updated 2023 Guidance Adjusted to include the anticipated effects and expected impact of current macroeconomic headwinds. Bookings¹ Total Revenues Product Revenues Service Revenues Technical Services Revenues Advanced Services Revenues Non-GAAP EBITDA Non-GAAP EPS Q4-2023 Not guided $247-$267 Million $142-$152 Million $105-$115 Million Not guided Not guided $9-$19 Million $0.07-$0.22 TY-2023 $850 Million -$950 Million $1.135-$1.155 Billion $705-$715 Million $430-$440 Million $222-$227 Million $208-$213 Million $123-$133 Million $1.65-$1.80 We do not provide a reconciliation of forward-looking non-GAAP guidance to the comparable GAAP measures as these items are inherently uncertain and difficult to estimate and cannot be predicted without unreasonable effort. 1. We define bookings generally as: (i) the value of non-cancelable contracts for our connected devices, software products, and Advanced Services (although, for those Advanced Services contracts without a minimum commitment, bookings only includes the amount of revenue that has been recognized once the services have been provided); and (ii) for our consumables, the value of orders placed through our Omnicell Storefront online platform or through written or telephonic orders. We typically exclude technical services and other less significant items ancillary to our products and services, such as freight revenue from bookings. 2. Represents estimated cumulative TAM over 10 years as of 5/31/2022 and includes the United States, UK&I, Germany, France, Spain, Kingdom of Saudi Arabia and Australia/New Zealand. © 2023 Omnicell, Inc. Long-Term Value Creation Opportunities Leadership position in the digital transformation of healthcare with $90 Billion+ TAM² Emerging and scaling of Advanced Services offerings Platform adoption, expansion, market share gains, and upgrade cycles supporting growth Strong balance sheet should enable transformation to new business model with expected higher gross margins, EBITDA, and free cash flows 16#17A Better Way: Our Environment, Social, Governance, and Innovation Strategy © 2023 Omnicell, Inc. Environment Innovating for Energy Efficiency Actively contribute to realize 1.5° Celsius future by 2030 Social Every Voice Counts Create a culture of inclusivity, engagement, and well-being to be an employer of choice Governance Doing the Right Thing Identify, prevent, and mitigate risk to Omnicell to create, preserve, and realize value Innovation Accelerating for Perfection Design and deliver our products to minimize our environmental footprint while maximizing patient outcomes 17#18A Better Way: Our Approach to ESG S Environment Innovating for Efficiency Actively contribute to realize 1.5° Celsius future by 2030 © 2023 Omnicell, Inc. Our Better Way JL Social Every Voice Counts Create a culture of inclusivity, engagement, and well-being to be an employer of choice DO Governance Doing the Right Thing Identify, prevent, and mitigate risk to Omnicell to create, preserve, and realize value Targets Risk Management Governance and Reporting Innovation Accelerating for Perfection Design and deliver our products to minimize our environmental footprint while maximizing patient outcomes Our Approach Omnicell uses a risk-based approach designed to strategically align our ESG goals and targets to address the risks we believe are most material to our organization In 2021, Omnicell identified 11 material topic areas that our internal and external stakeholders indicated are strategic or paramount to our business, and developed strategic goals and targets in response In 2022, we executed on strategic short-term actions and honed our strategy, making marked progress towards our targets and long-term goals Looking forward, we plan to continue reviewing these material topic areas to reflect the changing business and ESG&I landscape Significance of Our Approach Create a Competitive Advantage: We believe our robust ESG program is a credible, authentic "differentiator" from our competition Prepare Omnicell for Upcoming Regulation: As the regulatory landscape shifts toward mandatory reporting and disclosure, measuring ESG progress should help prepare Omnicell to be compliant with future requirements Enhance Resiliency with Relevant Goals & Targets: Year over year improvement towards our strategically-aligned public goals and targets is expected to increase Omnicell's adaptability and resilience 18#19A Better Way: ESG in Action Environment Decreased Scope 1 and 2 emissions in 2022 by 17% from 2021 ● ● Governance Recent Board refreshment with 5 new Directors added in the last 4 years Regularly evaluate Board composition Lead Independent Director with clear responsibilities Advancing our information security zero trust journey ● Conducted a Climate Risk Assessment to identify top risks to domestic operations and sites ● Implemented reusable foam inserts for XT cabinet drawer service shipments, reducing our foam packaging waste for single-deep drawers by 76% in 2022 Social Finalized creation of four Employee Resource Groups and established a Global Culture Committee ● ● ● Launched a charitable efforts platform, corporate matching program for employee donations, and paid Volunteer Time Off program intended to maximize social impact Innovation Working to formalize a charitable product donation program by 2024 ● Introduced new talent development programs and enhanced performance reviews and employee feedback mechanisms Earned a 2022 Retail Excellence (REX) Award in the Technology and Automation category for EnlivenHealth from Drug Store News Exploring opportunities to incorporate innovative processes and materials such as recycled materials and reducing material waste in our product design 2022 ESG Report Published third annual ESG Report in April 2023 90% of Board is independent 50% of Board are women or racially or ethnically diverse MSCI ESG RATINGS CCC B AA BB BBB A AA AAA © 2023 Omnicell, Inc. THE USE BY OMNICELL, INC. OF ANY MSCI ESG RESEARCH LLC OR ITS AFFILIATES ("MSCI") DATA, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT, RECOMMENDATION, OR PROMOTION OF OMNICELL, INC. BY MSCI. MSCI SERVICES AND DATA ARE THE PROPERTY OF MSCI OR ITS INFORMATION PROVIDERS AND ARE PROVIDED 'AS-IS' AND WITHOUT WARRANTY. MSCI NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI. 19#20We Expect that Omnicell is Positioned to Win Based on Our Belief that: Omnicell has the right solutions and the right business model to solve the medication management problem that the healthcare system is facing Omnicell is positioned as the leading strategic partner to health systems in large and growing market segments with $90 Billion+ TAM1¹ Omnicell is scaling Advanced Services to capitalize on the many growth opportunities ahead - with Advanced Services growth continuing to drive recurring revenue growth With a track record of strong financial performance and disciplined execution, Omnicell is poised to drive profitable growth Executing on our vision to deliver the most compelling automation and services that accelerate pharmacy perfection © 2023 Omnicell, Inc. 1. Represents estimated cumulative TAM over 10 years as of 5/31/2022 and includes the United States, UK&I, Germany, France, Spain, Kingdom of Saudi Arabia and Australia/New Zealand. 20#21Appendix#22© 2023 Omnicell, Inc. Reconciliation of GAAP revenues to non-GAAP revenues: GAAP revenues Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Acquisition accounting impact related to deferred revenues Non-GAAP revenues Reconciliation of GAAP gross profit to non-GAAP gross profit: GAAP gross profit GAAP gross margin Share-based compensation expense Amortization of acquired intangibles Acquisition accounting impact related to deferred revenues Ransomware-related expenses, net of insurance recoveries Severance-related expenses, net of reversals Non-GAAP gross profit Non-GAAP gross margin Reconciliation of GAAP operating expenses to non-GAAP operating expenses: GAAP operating expenses GAAP operating expenses % to total revenues Share-based compensation expense Amortization of acquired intangibles (d) $ $ $ $ Three Months Ended September 30, 2023 $ 298,663 $ 298,663 $ 131,964 44.2% 45.7% (280) 136,530 $ 2,213 2,633 128,252 42.9% (12,769) (5,050) (246) $ 184 (1,348) 301 109,324 36.6% $ 2022 $ 348,059 183 348,242 159,095 45.7% 2,203 3,238 183 95 444 165,258 Acquisition-related expenses Impairment and abandonment of operating lease right-of-use and other assets related to facilities Ransomware-related expenses, net of insurance recoveries Executives transition costs Severance-related and other expenses, net of reversals (d) Non-GAAP operating expenses Non-GAAP operating expenses as a % of total non-GAAP revenues For the three months ended September 30, 2022, other expenses included approximately $0.7 million of certain litigation expenses. 47.5% 140,630 40.4% (15,107) (5,507) (251) (297) (932) (2,050) 116,486 33.4% 22#23© 2023 Omnicell, Inc. Reconciliation of GAAP income from operations to non-GAAP income from operations: GAAP income from operations Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) GAAP operating income % to total revenues Share-based compensation expense Amortization of acquired intangibles Acquisition accounting impact related to deferred revenues Acquisition-related expenses Impairment and abandonment of operating lease right-of-use and other assets related to facilities Ransomware-related expenses, net of insurance recoveries Executives transition costs Severance-related and other expenses, net of reversals (d) Non-GAAP income from operations Non-GAAP operating margin (non-GAAP operating income as a % of total non-GAAP revenues) Reconciliation of GAAP net income to non-GAAP net income: GAAP net income Share-based compensation expense Amortization of acquired intangibles Acquisition accounting impact related to deferred revenues. (a) (d) Acquisition-related expenses Impairment and abandonment of operating lease right-of-use and other assets related to facilities Ransomware-related expenses, net of insurance recoveries Tax effect of the adjustments above (¹) Non-GAAP net income Executives transition costs Severance-related and other expenses, net of reversals (d) Amortization of debt issuance costs $ $ $ $ Three Months Ended September 30, 2023 1.2% 9.1% 3,712 $ 14,982 7,683 246 (184) 1,348 (581) 27,206 $ 5,553 $ 14,982 7,683 246 (184) 1,348 (581) 1,048 (2,008) 28,087 $ 2022 5.3% 14.0% 18,465 17,310 8,745 183 251 297 1,027 2,494 48,772 16,774 17,310 8,745 183 251 297 1,027 2,494 1,042 (2,948) 45,175 Tax effects calculated for all adjustments except share-based compensation expense, using an estimated annual effective tax rate of 21% for both fiscal years 2023 and 2022. For the three months ended September 30, 2022, other expenses included approximately $0.7 million of certain litigation expenses. 23#24© 2023 Omnicell, Inc. Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Reconciliation of GAAP net income per share - diluted to non-GAAP net income per share - diluted: Shares diluted GAAP Shares diluted non-GAAP (b) GAAP net income per share - diluted Share-based compensation expense Amortization of acquired intangibles Acquisition accounting impact related to deferred revenues Acquisition-related expenses Impairment and abandonment of operating lease right-of-use and other assets related to facilities Ransomware-related expenses, net of insurance recoveries Executives transition costs Severance-related and other expenses, net of reversals Amortization of debt issuance costs Non-GAAP dilutive shares impact from convertible note hedge transaction (b) Tax effect of the adjustments above (2) Non-GAAP net income per share - diluted Reconciliation of GAAP net income to non-GAAP EBITDA): GAAP net income Share-based compensation expense Interest (income) and expense, net Depreciation and amortization expense Acquisition accounting impact related to deferred revenues Acquisition-related expenses Impairment and abandonment of operating lease right-of-use and other assets related to facilities Ransomware-related expenses, net of insurance recoveries Executives transition costs Severance-related and other expenses, net of reversals (d) Amortization of debt issuance costs Provision for income taxes Non-GAAP EBITDA Non-GAAP EBITDA margin (non-GAAP EBITDA as a % of total non-GAAP revenues) (2) (b) $ $ $ Three Months Ended September 30, 2023 2022 $ 13.6% 45,595 45.595 0.12 0.33 0.16 0.01 (0.00) 0.03 (0.01) 0.02 (0.04) 0.62 5,553 14,982 (5,247) 21,542 246 $ $ $ (184) 1,348 (581) 1,048 1,829 40.536 $ 17.4% 45,819 45,384 0.37 0.38 0.19 0.00 0.01 0.01 0.02 0.06 0.02 0.00 (0.06) 1.00 16,774 17,310 (1,136) 21,826 183 251 297 1,027 Tax effects calculated for all adjustments except share-based compensation expense, using an estimated annual effective tax rate of 21% for both fiscal years 2023 and 2022. For the three months ended September 30, 2022, non-GAAP diluted shares excluded approximately 0.4 million shares related to the impact of dilutive convertible senior notes for which the Company is economically hedged through its anti-dilutive convertible note hedge transaction. (C) Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. (d) For the three months ended September 30, 2022, other expenses included approximately $0.7 million of certain litigation expenses. 2,494 1,042 543 60,611 24#25Reconciliation of GAAP net income (loss) to non-GAAP EBITDA (¹): GAAP net income (loss) Share-based compensation expense Interest (income) and expense, net Depreciation and amortization expense Acquisition accounting impact related to deferred revenues Acquisition-related expenses Impairment and abandonment of operating lease right-of-use and other assets related to facilities Ransomware-related expenses, net of insurance recoveries Executives transition costs Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Severance-related and other expenses, net of reversals Amortization of debt issuance costs © 2023 Omnicell, Inc. $ Three Months Ended September 30, 2023 5.553 $ 14,982 (5,247) 21,542 Three Months Ended June 30, 2023 246 3,451 14,089 (4,410) 22,080 246 Three Months Ended March 31, 2023 S (15,000) $ 14,042 (3,074) 21,974 Three Months Ended December 31, 2022 246 8,420 (184) 1,348 841 (581) 721 5,314 1,048 1,046 Provision for (benefit from) income taxes 8,758 1,829 40,536 1,045 (6,182) 26,785 $ Non-GAAP EBITDA $ 46,822 $ (a) Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. (28,408) 17,516 (2,410) 22,088 40 246 3,992 73 - 18,782 1,043 (7,106) 25,856 Year Ended December 31, 2017 30,518 21,857 6,072 51,511 1,252 1,715 4,752 (26,006) 91,671 25#26Convertible senior notes, net Cash and cash equivalents Net debt Net debt/Non-GAAP EBITDA Long-term debt, current portion, net Long-term debt, net Total debt, net Cash and cash equivalents Net debt Net debt/Non-GAAP EBITDA (a) © 2023 Omnicell, Inc. (a) $ $ $ $ Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Quarter Ended September 30, 2023 $ Year Ended December 31, 2017 568,887 (446,840) 122,047 0.9 15,208 194,917 210,125 (32,424) 177,701 1.9 (a) Net Debt / EBITDA = (Total Debt - Cash and Cash Equivalents) / Trailing Twelve Months Non-GAAP EBITDA Revolver availability Cash and cash equivalents Liquidity Revolver availability Cash and cash equivalents Liquidity Quarter Ended September 30, 2023 500,000 446,840 946,840 $ $ Year Ended December 31, 2017 $ $ 280,500 32,424 312,924 26#27Omnicell